In this review, the process of CAR-T cell engineering and different generations of these cells will be summarised, highlighting their potential use in treating HNSCC through targeting ErbB and MUC1; TAAs highly expressed by this solid tumour. The gene discussed is MUC1; the disease is head and neck squamous cell carcinoma.